Please assess the completion status of the following clinical trial:

Trial Title: Infliximab in Treating Cancer-Related Fatigue in Postmenopausal Women Who Have Undergone Treatment for Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Women who report elevated fatigue following cancer diagnosis and treatment~Exclusion Criteria:~* Women who have medical conditions that may affect the immune system or are associated with baseline fatigue syndrome, and/or who use medications that affect the immune system or fatigue.~* Women with major affective disorders and those with sleep or pain disorders.~* Presence of medical conditions that may but subject at undue risk for experimental procedures.~* Chronic or recurring infections, symptoms of chronic heart failure, demyelinating disorders, and those taking immunosuppressive medications.~* Neoplastic disease other than primary breast cancer~* Compromised cardiovascular function~* Insulin-dependent diabetes~* Neurological disorder~* Peripheral neuropathy~* Pregnancy~* Use of psychotropic medications within 2 weeks of screening~* Abnormal screening laboratory findings (i.e., creatinine \> 1.4mg%; anemia; abnormal thyroid hormone; hematuria; elevated liver function tests, low protein or albumin; fasting glucose \>120mg%; elevated FTI or TSH; positive TB screening, HIV screening or hepatitis C).~* Smokers

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Study Arm (Type: EXPERIMENTAL): Please see intervention description

Based on this trial design, predict the completion outcome and termination type (if applicable).